Evidence map›Paper›PMID 41916290›Full record

ArticleCell reports. Medicine2026

mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy.

Jiayan Fu, Yaoqi Liu, Zhenyu Zhong, Benyuan Cao, Luna Ran, Zijia Guo, Haiyang Dong, Nengcheng Bao, Rongqing Pan, Jinqiang Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiayan FuNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Yaoqi LiuNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Zhenyu ZhongMOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Benyuan CaoNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Luna RanNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Zijia GuoNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Haiyang DongNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Nengcheng BaoNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China.
Rongqing PanInstitute of Immunology, Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University, Hangzhou, China.
Jinqiang WangNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China.
Yuanhui MaoDepartment of Urology of The Second Affiliated Hospital & Liangzhu Laboratory, Zhejiang University, Hangzhou, China. Electronic address: yhmao_zju@zju.edu.cn.
Yongfeng JinNational Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China; MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, China; Emergency and Trauma Centre, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; School of Life Science, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: jinyf@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adoptive T cell therapy (ACT) holds promise for cancer immunotherapy, yet its clinical efficacy against solid tumors remains suboptimal. An emerging strategy aims to enhance ACT by modulating mitochondrial apoptosis (mtApoptosis) priming of cancer cells. This study develops an mRNA-based combinational strategy that utilizes mRNA lipid nanoparticles encoding BH3 domains from activator-type proteins to trigger robust mtApoptosis, thereby augmenting antitumor immunity with ACT. This approach preferentially induces immunogenic cell death in cancer cells and remodels the immunosuppressive microenvironment. Combined with ACT, the formulation synergistically enhances tumor cell killing in vitro by lowering the apoptotic threshold. In vivo, the combination improves therapeutic efficacy by boosting endogenous T cell cytotoxicity and mitigating ACT-induced T cell dysfunction. Single-cell transcriptomics further reveals that the combination reprograms effector T cells toward memory-like states with expanded TCR diversity. Collectively, this study proposes a combinatorial mRNA-based strategy and provides mechanistic insights for augmenting ACT through mtApoptosis priming.

Indexed as

ApoptosisImmunotherapy, AdoptiveLipidsMitochondriaNanoparticlesRNA, MessengerT-LymphocytesAnimalsCell Line, TumorHumansLiposomesMiceMice, Inbred C57BLLipid NanoparticlesLipidsLiposomesRNA, Messengeradoptive T cell therapymitochondrial apoptosissolid tumorsynergistic effecttherapeutic mRNA

Identifiers

PMID41916290
PMCPMC13130659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.